What is the appropriate methotrexate dosing regimen for an adult with atopic dermatitis who has normal renal and hepatic function and is not pregnant or breastfeeding?

Methotrexate Dosing for Adult Atopic Dermatitis

For adults with atopic dermatitis and normal renal/hepatic function, start methotrexate at 5-15 mg once weekly orally, with most patients requiring dose escalation to 15-25 mg weekly for optimal response. 1

Initial Dosing Strategy

The British Association of Dermatologists guidelines recommend starting methotrexate at 5-15 mg weekly in healthy adults 1. However, clinical trial evidence demonstrates that:

• Starting at 10-15 mg weekly is most commonly effective 2, 3
• A 5 mg test dose may be given initially to detect extreme sensitivity to adverse effects 1
• Starting at the lower end (10 mg) with incremental increases of 2.5 mg weekly until response is achieved represents a practical approach 2

Dose Escalation and Maintenance

Most patients require dose escalation beyond initial doses:

• Clinical trials show that 15 mg weekly is often insufficient as monotherapy, with only 8% of patients achieving adequate response at this dose by week 8 3
• Increasing to 25 mg weekly produces significant improvement, with 92% of patients achieving 50% reduction in disease severity by week 20 3
• The median effective dose is 15 mg weekly, though individual requirements vary 2
• Maximum dose should not ordinarily exceed 30 mg weekly 1

Important Caveat on Dose Response

Evidence suggests that patients who fail to respond adequately by week 12 despite reaching 15 mg weekly are unlikely to benefit from further dose escalation 2. This represents a critical decision point to consider alternative therapies.

Route of Administration

• Oral administration is preferred for standard dosing 1
• Subcutaneous or intramuscular routes may improve absorption and reduce gastrointestinal side effects in patients with poor oral response 1

Timeline for Response

• Therapeutic benefit typically begins within 3-12 weeks 1
• Majority of improvement occurs by week 12 2
• Consider switching to alternative medication if minimal efficacy is achieved within 12-16 weeks 1

Essential Concurrent Therapy

Folic acid supplementation is strongly recommended (Grade A recommendation) 1. The typical dose is 5 mg weekly, though specific dosing is not detailed in the guidelines.

Monitoring Requirements

Intensive initial monitoring is mandatory:

• FBC, LFTs, and U&E every 7-14 days for the first month 1
• Once stabilized: every 2-3 months 1
• Patients unable to comply with monitoring should not receive methotrexate 1

Critical Safety Considerations

Before prescribing, ensure:

• Effective contraception is in place (pregnancy is contraindicated) 1
• Patient understands weekly dosing schedule (not daily) 1
• Patient can recognize signs of toxicity: fever, mouth ulcers, unexplained bruising, nausea, breathlessness 1
• Pneumococcal vaccine and yearly influenza vaccination are administered 1
• Alcohol intake is limited 1

Practical Algorithm

1. Week 0: Give 5 mg test dose (optional), then start 10-15 mg weekly with folic acid 5 mg weekly
2. Weeks 1-4: Monitor FBC/LFTs/U&E every 7-14 days
3. Weeks 4-12: Increase by 2.5-5 mg increments every 2-4 weeks if inadequate response, targeting 15-25 mg weekly
4. Week 12: If no response at 15 mg weekly, consider alternative therapy rather than further escalation
5. After stabilization: Monitor every 2-3 months; use lowest effective maintenance dose

The evidence demonstrates methotrexate is inferior to cyclosporine at low doses (15 mg weekly) but achieves comparable efficacy at higher doses (25 mg weekly) with potentially better tolerability long-term 3. This supports an aggressive dose escalation strategy in the first 12-20 weeks of treatment.